biguanides and Diabetes Mellitus, Adult-Onset studies

Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.

Research Excerpts

Excerpt	Relevance	Reference
" We herein report a case of cardiac dysfunction due to thiamine deficiency after hemodialysis in a patient with suspected biguanide-related lactic acidosis."	8.12	Cardiac Dysfunction Due to Thiamine Deficiency after Hemodialysis for Biguanide-related Lactic Acidosis. ( Jimura, F; Kachi, N; Tamaki, H; Tsushima, H, 2022)
" We herein present a case of biguanide-associated severe lactic acidosis complicated with thiamine deficiency that was provoked without predisposing factors for thiamine deficiency."	7.85	The Dramatic Recovery of a Patient with Biguanide-associated Severe Lactic Acidosis Following Thiamine Supplementation. ( Fujita, M; Godo, S; Kudo, D; Kushimoto, S; Nomura, R; Shimokawa, H; Yoshida, Y, 2017)
"A French analysis of reports of adverse effects shows that lactic acidosis due to metformin is preventable."	7.74	Metformin: preventable lactic acidosis. ( , 2007)
"The aim of the present study was to evaluate the relationship of C-peptide and the C-peptide/bloodsugar ratio with clinical/biochemical variables presenting a well-known association with insulin resistance in NIDDM patients in acceptable control, obtained without the use of exogenous insulin."	7.69	Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients. ( Acosta, D; Astorga, R; García de Pesquera, F; Losada, F; Morales, F; Pumar, A; Relimpio, F, 1997)
" Weight loss was greater in patients with lower baseline HbA1c and in patients taking concomitant biguanides."	5.22	Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. ( Iwamoto, N; Nishiyama, H; Ohyama, S; Onishi, Y; Oura, T; Takeuchi, M, 2016)
" Metformin, an antihyperglycemic drug of the biguanide class, may be effective in subjects with IGT by reducing hepatic glucose output, enhancing insulin sensitivity, or through other mechanisms such as weight loss."	4.79	[Drug therapy in subjects with impaired glucose tolerance]. ( Kawamori, R; Yoshii, H, 1996)
" We herein report a case of cardiac dysfunction due to thiamine deficiency after hemodialysis in a patient with suspected biguanide-related lactic acidosis."	4.12	Cardiac Dysfunction Due to Thiamine Deficiency after Hemodialysis for Biguanide-related Lactic Acidosis. ( Jimura, F; Kachi, N; Tamaki, H; Tsushima, H, 2022)
" We herein present a case of biguanide-associated severe lactic acidosis complicated with thiamine deficiency that was provoked without predisposing factors for thiamine deficiency."	3.85	The Dramatic Recovery of a Patient with Biguanide-associated Severe Lactic Acidosis Following Thiamine Supplementation. ( Fujita, M; Godo, S; Kudo, D; Kushimoto, S; Nomura, R; Shimokawa, H; Yoshida, Y, 2017)
" A multivariate analysis with multiple logistic regression revealed that visceral fat accumulation was inhibited in women and those taking statins or thiazolidines and aggravated in men and those with obesity or an increased waist circumference."	3.80	Estimation of visceral fat and fatty liver disease using ultrasound in patients with diabetes. ( Ichikawa, T; Kohno, S; Nakao, K; Onitsuka, Y; Takeshima, F, 2014)
"A French analysis of reports of adverse effects shows that lactic acidosis due to metformin is preventable."	3.74	Metformin: preventable lactic acidosis. ( , 2007)
"Our results conclude that 10% decrease in body mass index (BMI) among overweight patients, smoking cessation, initiation to undertake a preventive treatment with low-dose aspirin, initiation to undertake or intensify blood pressure control, initiation to undertake or intensify lipidic control, and shift to biguanides among overweight patients are factors associated with significant benefits (avoided costs) which compensate for the increase in treatment costs."	3.73	[Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France]. ( Crainich, D; Lebrun, T; Marissal, JP; Sailly, JC, 2005)
"The aim of the present study was to evaluate the relationship of C-peptide and the C-peptide/bloodsugar ratio with clinical/biochemical variables presenting a well-known association with insulin resistance in NIDDM patients in acceptable control, obtained without the use of exogenous insulin."	3.69	Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients. ( Acosta, D; Astorga, R; García de Pesquera, F; Losada, F; Morales, F; Pumar, A; Relimpio, F, 1997)
" The most dangerous side-effect of biguanides is lactic acidosis."	3.67	Incidence of severe sideeffects during therapy with sulfonylureas and biguanides. ( Berger, W, 1985)
"Japanese patients with type 2 diabetes and inadequate glycaemic control despite diet and/or exercise (n = 282), or despite diet and/or exercise plus one oral antidiabetic agent [sulphonylurea (n = 262), rapid-acting insulin secretagogue (n = 124), α-glucosidase inhibitor (n = 141), biguanide (n = 136), thiazolidinedione (n = 139) or dipeptidyl peptidase-4 inhibitor (n = 138)] were randomized to treatment with fasiglifam 25 or 50 mg once daily for 52 weeks."	2.82	Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study. ( Enya, K; Kaku, K; Matsuno, R; Nakaya, R; Ohira, T, 2016)
"Weight loss was observed with dulaglutide in combination with BG alone or with SU + BG."	2.82	The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes. ( Araki, E; Inagaki, N; Matsui, A; Oura, T; Takeuchi, M; Tanizawa, Y, 2016)
" The most frequent adverse events with dulaglutide treatment were nasopharyngitis and gastrointestinal symptoms."	2.80	Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. ( Araki, E; Imaoka, T; Inagaki, N; Oura, T; Takeuchi, M; Tanizawa, Y, 2015)
"Insulin treatment in patients with type 2 diabetes mellitus affects the expression of inflammatory cytokines and subsequently modifies the thrombotic mechanisms in patients with coronary atherosclerosis, independently from the duration of diabetes and the extend of coronary artery disease."	2.73	Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis. ( Antoniades, C; Bosinakou, E; Latsios, G; Marinou, K; Papageorgiou, N; Siasos, G; Stefanadi, E; Stefanadis, C; Tentolouris, C; Tousoulis, D; Tsioufis, C, 2007)
"group they classified 16 verified MODY/NIDDY patients."	2.67	[Is it permissible to treat young diabetics with oral antidiabetics?]. ( Gerö, L; Grósz, A; Halmos, T; Kautzky, L; Pánczél, P; Winkler, G, 1991)
" Further, the data available are derived from small, short-term registration trials and typically focus on relative rather than absolute risks of any given drug and do not address the potential adverse outcomes if a patient's diabetes remains untreated."	2.55	Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes? ( Grunberger, G, 2017)
"The management of type 1 diabetes remains a challenge for clinicians."	2.52	The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. ( Davis, SN; Munir, KM, 2015)
"Current strategies for the treatment of type 2 diabetes mellitus promote individualized plans to achieve target glucose levels on a patient-by-patient basis while minimizing treatment related risks."	2.49	Complications of diabetes therapy. ( Corathers, SD; Peavie, S; Salehi, M, 2013)
"A review of Type 2 diabetes mellitus is presented."	2.44	Type 2 diabetes: the many facets of care. ( Hall, MA, 2008)
"Gestational Diabetes is characterized by different degrees of glucose intolerance that produce a series of fetal and perinatal alterations."	2.44	[Effectiveness of oral hypoglycemic drugs in the metabolic control of patients with gestational diabetes]. ( Barrera H, C; Candía P, P; Lahsen M, R; Soto-Chacón, E; Valdés R, E, 2008)
"The secondary and adverse effects when biguanides, alpha-glycosidase inhibitor or thiazolidine derivative was used with sulphonylurea agent (SU) as compared with those with SU alone in Type 2 diabetes patients by using Systematic Review."	2.44	Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review. ( Eto, M; Katsuyama, S; Miura, M; Mohri, K; Mouri, K; Mukai, J; Shoji, T; Suzuki, T; Tada, H; Watanabe, Y, 2007)
"The majority of patients with type 2 diabetes mellitus are overweight or obese at the time of diagnosis, and obesity is a recognised risk factor for type 2 diabetes and coronary heart disease (CHD)."	2.44	Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. ( Hermansen, K; Mortensen, LS, 2007)
"The treatment of type 2 diabetes in a patient with CRF is a challenge for the general practitioner, because of the accumulation of drugs and/or specific metabolites."	2.44	[Chronic kidney disease and antidiabetic treatment]. ( Berwert, L; Teta, D; Zanchi, A, 2007)
"However, most patients with type 2 diabetes do not achieve target glycemic levels with traditional therapies, and these agents are also associated with hypoglycemia, weight gain, and poor tolerability."	2.44	Oral antidiabetic agents in type 2 diabetes. ( Levetan, C, 2007)
" These data include information regarding drug safety and efficacy and/or drug pharmacokinetic and drug dosing information."	2.43	The utility of oral diabetes medications in type 2 diabetes of the young. ( Abu-Baker, A; Busch, RS; Kane, MP, 2005)
"In the treatment of elderly type 2 diabetes, it is important to detect hypoglycemia correctly, because the elderly patients often exhibit atypical symptoms from hypoglycemia."	2.43	[Knack of treatment with oral hypoglycemic drugs in the elderly]. ( Hashizume, K; Komatsu, M, 2006)
"Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term."	2.43	Oral antidiabetic agents: current role in type 2 diabetes mellitus. ( Bailey, CJ; Krentz, AJ, 2005)
"In patients with type 2 diabetes mellitus, the traditional method of initiating therapy with a sulfonylurea and increasing the dosage until maximum levels are reached before adding an insulin-sensitizing agent has persisted and should be re-evaluated."	2.42	A comparison of agents used to manage type 2 diabetes mellitus: need for reappraisal of traditional approaches. ( Bell, DS, 2004)
"Insulin resistance is the most prominent feature common in both type 2 diabetes and its associated metabolic abnormalities."	2.42	Insulin sensitizers. ( Basu, A; Kudva, YC; Zangeneh, F, 2003)
"Currently available oral agents for the treatment of type 2 diabetes mellitus include a variety of compounds from 5 different pharmacologic classes with differing mechanisms of action, adverse effect profiles, and toxicities."	2.41	Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. ( Beattie, P; Harrigan, RA; Nathan, MS, 2001)
"Hyperglycemia in patients with type 2 diabetes mellitus is caused by peripheral insulin resistance, which results in decreased insulin-mediated glucose disposal and increased endogenous glucose production, and inadequate insulin secretion."	2.41	[Clinical difference between thiazolidinediones and biguanides]. ( Hotta, N, 2001)
" When multiple dosages of a drug were tested, the results of the highest approved dosage were used."	2.41	Oral antihyperglycemic therapy for type 2 diabetes: scientific review. ( Inzucchi, SE, 2002)
"Because insulin resistance is an underlying pathologic defect in patients with type 2 diabetes, agents that increase insulin sensitivity should be used early in the course of therapy."	2.41	Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus. ( Weissman, P, 2002)
"The similarity between gestational diabetes mellitus and type 2 diabetes is highlighted."	2.41	When diet fails: insulin and oral hypoglycemic agents as alternatives for the management of gestational diabetes mellitus. ( Langer, O, 2002)
"Optimal treatment for type 2 diabetes mellitus should aim to improve insulin resistance and the associated cardiovascular risk factors in addition to achieving glycaemic control."	2.41	Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? ( Campbell, IW, 2000)
"Lactic acidosis is a broad-anion gap metabolic acidosis caused by lactic acid overproduction or underutilization."	2.41	Lactic acidosis update for critical care clinicians. ( Luft, FC, 2001)
"Type 2 diabetes is defined as a syndrome characterized by insulin deficiency, insulin resistance and increased hepatic glucose output."	2.41	Oral agents in the management of type 2 diabetes mellitus. ( Feinglos, MN; Luna, B, 2001)
"Type 2 diabetes mellitus is characterized by insulin deficiency but in particular by insulin resistance."	2.41	[Current and future aspects of oral antidiabetic agents in type 2 diabetes]. ( Rybka, J, 2001)
"Type 2 diabetes is understood to result most often from insulin resistance and insulin deficiency."	2.41	Type 2 diabetes. How new insights, new drugs are changing clinical practice. ( Drexler, AJ; Robertson, C, 2001)
"Patients who develop NIDDM at age 65 years may live long enough to develop microvascular complications."	2.40	Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus. ( Jennings, PE, 1997)
"Biguanides have been used in treatment of diabetes mellitus for over 30 years now."	2.40	[Value of biguanide in therapy of diabetes mellitus]. ( Haupt, E; Panten, U, 1997)
"Although most patients with type 2 diabetes mellitus can be initially managed with diet and exercise alone, most eventually require at least oral agents if not insulin to maintain glycemic control."	2.40	Treatment of type 2 diabetes mellitus. ( Bethel, MA; Feinglos, MN, 1998)
" Despite historic reliance on these agents to treat type 2 diabetes, long-term use of SUs may desensitize beta cells."	2.40	Effects of current therapeutic interventions on insulin resistance. ( Kobayashi, M, 1999)
"In the treatment of type 2 diabetes (NIDDM) we possess three groups of oral hypoglycaemic drugs: sulfonyl urea derivatives, biguanides (metformin) and alpha-glucosidase (acarbose) inhibitors."	2.40	[Pitfalls in treatment with oral antidiabetic agents]. ( Perusicová, J, 1998)
"Metformin is a biguanide that can used alone or in combination with sulfonylureas or insulin in the treatment of non-insulin-dependent diabetes mellitus (NIDDM)."	2.39	Metformin: a new treatment option for non-insulin-dependent diabetes mellitus. ( Bjelajac, A; Carson, DS; Goo, AK, 1996)
"impaired glucose tolerance (IGT) and NIDDM, conveys a great risk of macrovascular disease."	2.39	Oral antidiabetic drugs: an overview. ( Melander, A, 1996)
"The initial management of NIDDM should include patient education, dietary counselling and individualized programs of physical activity."	2.38	Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes. ( Castillo, MJ; Lefèbvre, PJ; Scheen, AJ, 1993)
"The biguanides are a class of oral hypoglycemic agents that are commonly used in the treatment of diabetes mellitus."	2.38	Biguanide-associated lactic acidosis. Case report and review of the literature. ( Arieff, AI; Barr, J; Gan, SC; Pearl, RG, 1992)
" The bioavailability of the biguanides ranges from 40 to 60%."	2.38	Pharmacokinetic optimisation of oral hypoglycaemic therapy. ( di Carlo, A; Giannarelli, R; Marchetti, P; Navalesi, R, 1991)
" By using labelled compounds or measuring the circulating concentrations, the main pharmacokinetic properties of oral hypoglycaemic agents have been assessed and, in some cases, their pharmacokinetic-pharmacodynamic relationships have been evaluated."	2.38	Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. ( Marchetti, P; Navalesi, R, 1989)
"Diabetes is a risk factor for Alzheimer's disease and related dementias (ADRD)."	1.62	Alzheimer's Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort. ( Barthold, D; Crane, PK; Dirk Keene, C; Gibbons, LE; Grabowski, TJ; Gray, SL; Larson, EB; Marcum, ZA; Postupna, N, 2021)
"Nocturnal hypoglycemia is a serious complication of insulin-treated diabetes, and it is often asymptomatic."	1.56	A Novel CGM Metric-Gradient and Combining Mean Sensor Glucose Enable to Improve the Prediction of Nocturnal Hypoglycemic Events in Patients with Diabetes. ( Bao, Y; Kandwal, A; Li, J; Liu, Y; Lu, J; Lu, W; Ma, X; Nie, Z; Tobore, I; Wang, L; Zhou, J, 2020)
" The percentage of patients with good adherence (the proportion of days in which patients took all pills as prescribed in the past 7 days ≥80%) was high (≥90%) in any dosing regimen with no significant difference among the groups."	1.51	[Adherence to Oral Antihyperglycemic Agents (Dipeptidyl Peptidase-4 Inhibitors and Biguanides) and Its Associated Factors in Patients with Type 2 Diabetes]. ( Hayashi, A; Kamei, M; Kubo, T; Okuyama, K; Tokita, S, 2019)
" Dynamic observation of certain ophthalmologic (visual acuity, macular thickness zone) and system functional parameters (lipid fractions content in serum) in long-term use of this medical drug in 20 patients with diabetes type 2 and DMO for 8 months."	1.46	[CHANGES OF LIFETIME MORPHOLOGICAL PARAMETERS OF THE RETINA ON THE BACKGROUND OF CORRECTION OF LIPID METABOLISM IN PATIENTSWITH TYPE 2 DIABETES MELLITUS]. ( Veselovskaya, NN, 2017)
"Metformin was rediscovered in the search for antimalarial agents in the 1940s and, during clinical tests, proved useful to treat influenza when it sometimes lowered blood glucose."	1.46	Metformin: historical overview. ( Bailey, CJ, 2017)
" Conclusion In many cases in the therapeutic inertia group only a single type of hypoglycaemic drug was prescribed or the dosage remained unchanged."	1.43	Therapeutic inertia and intensified treatment in diabetes mellitus prescription patterns: A nationwide population-based study in Taiwan. ( Huang, LY; Lai, MS; Shau, WY; Su, S; Yang, MC; Yeh, HL, 2016)
"Biguanides also inhibit mitochondrial ATP synthase, and two of them inhibit only ATP hydrolysis, not synthesis."	1.40	Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. ( Bridges, HR; Hirst, J; Jones, AJ; Pollak, MN, 2014)
"To analyse the association between cancer incidence and oral diabetes therapy (biguanide, sulphonylurea, thiazolidinedione and meglitinide) in men and women with type 2 diabetes mellitus."	1.40	Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus. ( Kashyap, SR; Kattan, MW; Raghavan, D; Sun, GE; Wells, BJ; Yip, K; Zimmerman, R, 2014)
"We enrolled 106 patients with type 2 diabetes mellitus (T2DM), treated with liraglutide (N."	1.40	Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide. ( Abiru, N; Ando, T; Fujishima, K; Haraguchi, A; Imaizumi, M; Kawakami, A; Matsumoto, K; Mori, F; Takamura, N; Yamasaki, H, 2014)
"Individuals with type 2 diabetes (T2DM) are at increased risk of cardiovascular disease, including heart failure (HF)."	1.39	Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes. ( Czlonkowski, A; Filipiak, KJ; Kaplon-Cieslicka, A; Opolski, G; Postula, M; Rosiak, M; Trzepla, E, 2013)
"In the treatment of type 2 diabetes aimed at prevention of cardiovascular events impacting the prognosis of affected patients, it is critically important not only to lower HbAlc values but to find a way to improve postprandial hyperglycemia without causing hypoglycemia thus minimizing drastic glycemic variations or to maintain favorable glycemic control with daily glycemic variations in mind."	1.37	[Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents]. ( Mori, Y, 2011)
"Insulin resistance is a major pathogenesis underlying the development of hyperglycemia and cardiovascular diseases in type 2 diabetes."	1.36	[Difference between biguanide and thiazolidinedione, and the significance of combination therapy of biguanide and thiazolidinedione]. ( Masuda, K; Terauchi, Y, 2010)
"To estimate the prevalence of type 2 diabetes in Italy and to investigate patient-related variables associated with the use of different antihyperglycemic therapies."	1.35	Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: a 4-year retrospective study from national primary care data. ( Allen, E; Boye, KS; Cottrell, S; Cricelli, C; Filippi, A; Mazzaglia, G; Medea, G; Trifirò, G; Yurgin, N, 2008)
"we studied a group of 268 patients with type 2 diabetes, aged between 30 and 50 years, with a diabetes duration of less than 5 years."	1.32	The value of basal C peptide and its relationship with pancreatic autoantibodies in young adults with type 2 diabetes mellitus. ( Roşu, M; Serban, V; Sima, A; Timar, R; Vlad, A, 2004)
"We screened 600 patients with type 2 diabetes treated with biguanides (phenformin or metformin) for a mean of 11."	1.32	Should we screen diabetic patients using biguanides for megaloblastic anaemia? ( Bonovas, S; Filioussi, K; Katsaros, T, 2003)
"Physicians should also recognize that type 2 diabetes is a multisystem disorder that requires multidisciplinary care, including education and ongoing counseling for effective patient self-management of the disease."	1.31	Oral antihyperglycemic therapy for type 2 diabetes: clinical applications. ( Holmboe, ES, 2002)
"in 22 NIDDM subjects refractory to a combination of Sulphonylureas and Biguanides was analysed."	1.28	Effect of bed time intermediate acting insulin in NIDDM subjects refractory to a combination of sulphonylureas and biguanides. ( Madhavan, R; Sankaran, JR; Seshasaianam, C; Seshiah, V; Shanker, R; Sundaram, A; Venkataraman, S, 1992)
"No metformin related cases were found."	1.28	Biguanide related lactic acidosis: incidence and risk factors. ( Aguilar, C; García, JE; Reza, A; Rull, JA, 1992)
"Biguanides were found to be conducive to normalization of thrombelastogram values, not elevating the blood serum content of lactic acid even after exercise test."	1.28	[Effect of biguanides on the indicators of thrombelastography and the level of lactic acid in diabetes mellitus]. ( Babenko, AIu; Blagosklonnaia, IaV; Krasil'nikova, EI; Zaĭed, N, 1990)

Research

Studies (209)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Change From Baseline in HbA1c

Timeframe	Studies, this research(%)	All Research%
pre-1990	24 (11.48)	18.7374
1990's	46 (22.01)	18.2507
2000's	69 (33.01)	29.6817
2010's	60 (28.71)	24.3611
2020's	10 (4.78)	2.80

Authors	Studies
Uehira, Y	1
Ueno, H	1
Ebihara, E	1
Uchida, T	1
Nabekura, H	1
Sakoda, H	1
Yonekawa, T	1
Yamaguchi, H	1
Nakazato, M	1
Tamaki, H	1
Tsushima, H	1
Kachi, N	1
Jimura, F	1
Sunnarborg, K	1
Tiihonen, M	1
Huovinen, M	1
Koponen, M	1
Hartikainen, S	1
Tolppanen, AM	1
Iketani, R	1
Imai, S	1
Hayashi, A	1
Kubo, T	1
Okuyama, K	1
Tokita, S	1
Kamei, M	1
van den Heuvel, JM	1
Farzan, N	1
van Hoek, M	1
Maitland-van der Zee, AH	1
Ahmadizar, F	1
Preiser, JC	1
Provenzano, B	1
Mongkolpun, W	1
Halenarova, K	1
Cnop, M	1
Li, J	1
Ma, X	1
Tobore, I	1
Liu, Y	1
Kandwal, A	1
Wang, L	1
Lu, J	1
Lu, W	1
Bao, Y	1
Zhou, J	1
Nie, Z	1
Kurmaz, SV	1
Fadeeva, NV	1
Ignat'ev, VM	1
Kurmaz, VA	1
Kurochkin, SA	1
Emel'yanova, NS	1
Kathuria, D	1
Raul, AD	1
Wanjari, P	1
Bharatam, PV	1
Barthold, D	1
Gibbons, LE	1
Marcum, ZA	1
Gray, SL	1
Dirk Keene, C	1
Grabowski, TJ	1
Postupna, N	1
Larson, EB	1
Crane, PK	1
Huang, LY	1
Yeh, HL	1
Yang, MC	1
Shau, WY	1
Su, S	1
Lai, MS	1
Shafiei-Irannejad, V	1
Samadi, N	1
Salehi, R	1
Yousefi, B	1
Zarghami, N	1
Śliwczyński, A	1
Brzozowska, M	1
Jacyna, A	1
Iltchev, P	1
Iwańczuk, T	1
Wierzba, W	1
Marczak, M	1
Orlewska, K	1
Szymański, P	1
Orlewska, E	1
Abbas, SY	2
Basyouni, WM	2
El-Bayouk, KAM	1
Tohamy, WM	1
Aly, HF	2
Arafa, A	2
Soliman, MS	2
Sanchez-Rangel, E	1
Inzucchi, SE	3
Bailey, CJ	5
Rena, G	1
Hardie, DG	2
Pearson, ER	1
El Shehry, MF	1
El-Bayouki, KAM	1
Chu, WM	1
Ho, HE	1
Huang, KH	1
Tsan, YT	1
Liou, YS	1
Wang, YH	1
Lee, MC	1
Li, YC	1
Arner, P	1
Kulyté, A	1
Batchelor, K	1
Laurencikiene, J	1
Livingston, J	1
Rydén, M	1
Veselovskaya, NN	1
Herrera-Martínez, AD	1
Pedraza-Arevalo, S	1
L-López, F	1
Gahete, MD	1
Gálvez-Moreno, MA	1
Castaño, JP	1
Luque, RM	1
Francini, F	1
Schinella, GR	1
Ríos, JL	1
Babenko, AY	1
Savitskaya, DA	1
Kononova, YA	1
Trofimova, AY	1
Simanenkova, AV	1
Vasilyeva, EY	1
Shlyakhto, EV	1
Hotta, N	2
Komamine, M	1
Kajiyama, K	1
Ishiguro, C	1
Uyama, Y	1
Chekmareva, IA	1
Blatun, LA	1
Paskhalova, YS	1
Mitish, VA	1
Paklina, OV	1
Terekhova, RP	1
Sepeda, P	1
Magomedova, SD	1
Ushakov, AA	1
Sokov, SL	1
Cabreiro, F	2
Au, C	1
Leung, KY	1
Vergara-Irigaray, N	1
Cochemé, HM	1
Noori, T	1
Weinkove, D	1
Schuster, E	1
Greene, ND	1
Gems, D	1
Inagaki, N	3
Watada, H	1
Murai, M	1
Kagimura, T	1
Gong, Y	1
Patel, S	1
Woerle, HJ	2
Sheehan, ME	1
Wagner, LF	1
Sun, GE	1
Wells, BJ	1
Yip, K	1
Zimmerman, R	1
Raghavan, D	1
Kattan, MW	1
Kashyap, SR	1
Knapen, LM	1
Dittrich, ST	1
de Vries, F	1
Starup-Linde, J	1
Vestergaard, P	1
Henry, RM	1
Stolk, LM	1
Neef, C	1
Bazelier, MT	1
Corathers, SD	1
Peavie, S	1
Salehi, M	1
Rosiak, M	1
Postula, M	1
Kaplon-Cieslicka, A	1
Trzepla, E	1
Czlonkowski, A	1
Filipiak, KJ	1
Opolski, G	1
Umetsu, R	1
Nishibata, Y	1
Abe, J	1
Suzuki, Y	1
Hara, H	1
Nagasawa, H	1
Kinosada, Y	1
Nakamura, M	1
Onitsuka, Y	1
Takeshima, F	1
Ichikawa, T	1
Kohno, S	1
Nakao, K	1
Giorda, CB	1
Nada, E	1
Tartaglino, B	1
Marafetti, L	1
Gnavi, R	1
Bridges, HR	1
Jones, AJ	1
Pollak, MN	1
Hirst, J	1
Haraguchi, A	1
Fujishima, K	1
Ando, T	1
Mori, F	1
Imaizumi, M	1
Abiru, N	1
Yamasaki, H	1
Matsumoto, K	1
Takamura, N	1
Kawakami, A	1
Emami-Riedmaier, A	1
Schaeffeler, E	1
Nies, AT	1
Mörike, K	1
Schwab, M	1
Araki, E	3
Tanizawa, Y	3
Tanaka, Y	3
Taniguchi, A	1
Koiwai, K	1
Kim, G	1
Salsali, A	1
Broedl, UC	1
Ohta, A	1
Goonesekera, SD	1
Yang, MH	1
Hall, SA	1
Fang, SC	1
Piccolo, RS	1
McKinlay, JB	1
Oura, T	3
Takeuchi, M	3
Imaoka, T	1
Munir, KM	1
Davis, SN	1
Tanabe, M	1
Nomiyama, T	1
Motonaga, R	1
Murase, K	1
Yanase, T	1
Pryor, R	1
Onishi, Y	1
Nishiyama, H	1
Ohyama, S	1
Iwamoto, N	1
Hunt, S	1
Kaku, K	1
Enya, K	1
Nakaya, R	1
Ohira, T	1
Matsuno, R	1
Tahrani, AA	1
Barnett, AH	1
Matsui, A	1
Kashyap, S	1
Kheniser, K	1
Li, L	1
Bena, J	1
Kasumov, T	1
Grunberger, G	2
Chen, L	1
Rodriguez, A	1
Tinahones, FJ	1
Jacober, SJ	1
Bue-Valleskey, J	1
Godo, S	1
Yoshida, Y	1
Fujita, M	1
Kudo, D	1
Nomura, R	1
Shimokawa, H	1
Kushimoto, S	1
Fujihara, K	1
Igarashi, R	1
Matsunaga, S	1
Matsubayashi, Y	1
Yamada, T	1
Yokoyama, H	1
Tanaka, S	1
Shimano, H	1
Maegawa, H	1
Yamazaki, K	1
Kawai, K	1
Sone, H	1
Hall, MA	1
Valdés R, E	1
Soto-Chacón, E	1
Lahsen M, R	1
Barrera H, C	1
Candía P, P	1
McNamara, DB	1
Murthy, SN	1
Fonseca, AN	1
Desouza, CV	1
Kadowitz, PJ	1
Fonseca, VA	1
Ben Amara, H	1
Kacem, A	1
Gaigi, I	1
Dakhli, S	1
Ben Mami, F	1
Achour, A	1
Kawamori, R	2
Iwamoto, Y	2
Kadowaki, T	1
Iwasaki, M	1
Kim, SW	1
Woo, JT	1
Baik, SH	1
Yoon, KH	1
Longo, R	1
Masuda, K	1
Terauchi, Y	1
Phung, OJ	1
Sood, NA	1
Sill, BE	1
Coleman, CI	1
Chaudhuri, A	1
Dandona, P	1
Takahashi, T	1
Odawara, M	1
Mori, Y	1
Manolopoulos, VG	1
Ragia, G	1
Tavridou, A	1
Furukawa, S	1
Kumagi, T	1
Miyake, T	1
Ueda, T	1
Niiya, T	1
Nishino, K	1
Murakami, S	1
Murakami, M	1
Matsuura, B	1
Onji, M	1
Hirose, T	1
Sim, YB	1
Park, SH	1
Kang, YJ	1
Kim, SS	1
Kim, CH	1
Kim, SJ	1
Jung, JS	1
Ryu, OH	1
Choi, MG	1
Suh, HW	1
Miller, RA	1
Chu, Q	1
Xie, J	1
Foretz, M	1
Viollet, B	1
Birnbaum, MJ	1
Guthrie, RM	1
Weissman, P	1
Langer, O	1
Okubo, M	1
Yamane, K	1
Kohno, N	1
Fujimoto, S	2
Shiba, T	1
Yamasaki, Y	1
Kuroda, A	1
Kitamura, R	1
Kitaoka, H	1
Merlob, P	1
Levitt, O	1
Stahl, B	1
Sakura, H	1
Cavallero, E	1
Dachet, C	1
Assadolahi, F	1
Martin, C	1
Navarro, N	1
Ansquer, JC	1
Corda, C	1
Foucher, C	1
Juhan-Vague, I	1
Jacotot, B	1
Zangeneh, F	1
Kudva, YC	1
Basu, A	1
Filioussi, K	1
Bonovas, S	1
Katsaros, T	1
Sutherland, JE	1
Hoehns, JD	1
Fisman, EZ	1
Tenenbaum, A	1
Motro, M	1
Adler, Y	1
Vlad, A	1
Serban, V	1
Sima, A	1
Timar, R	1
Roşu, M	1
Cheng, AY	1
Fantus, IG	1
Krentz, AJ	2
Bell, DS	1
Ishida, W	1
Satoh, J	1
Purnell, JQ	1
Weyer, C	1
Ruiz López, D	1
Marazuela Azpiroz, M	1
Yamada, Y	1
Marissal, JP	1
Sailly, JC	1
Crainich, D	1
Lebrun, T	1
Komatsu, M	1
Hashizume, K	1
Graue, N	1
Grabbe, S	1
Dissemond, J	1
Schatz, H	1
Uwaifo, GI	1
Ratner, RE	1
Levetan, C	1
Berwert, L	1
Teta, D	1
Zanchi, A	1
Monami, M	1
Marchionni, N	1
Masotti, G	1
Mannucci, E	1
Mintz, ML	1
Antoniades, C	1
Tousoulis, D	1
Marinou, K	1
Papageorgiou, N	1
Bosinakou, E	1
Tsioufis, C	1
Stefanadi, E	1
Latsios, G	1
Tentolouris, C	1
Siasos, G	1
Stefanadis, C	1
Scemons, D	1
Modi, P	1
Batsis, JA	1
Nieto-Martinez, RE	1
Lopez-Jimenez, F	1
Mukai, J	1
Tada, H	1
Watanabe, Y	1
Miura, M	1
Katsuyama, S	1
Shoji, T	1
Mohri, K	1
Mouri, K	1
Eto, M	1
Suzuki, T	1
Izumi, R	1
Hurt, J	1
Maki, KC	1
Bell, M	1
Zavras, AI	1
McCamish, M	1
Hermansen, K	1
Mortensen, LS	1
Kane, MP	1
Abu-Baker, A	1
Busch, RS	1
Mizuno, CS	1
Chittiboyina, AG	1
Kurtz, TW	1
Pershadsingh, HA	1
Avery, MA	1
Mazzaglia, G	1
Yurgin, N	1
Boye, KS	1
Trifirò, G	1
Cottrell, S	1
Allen, E	1
Filippi, A	1
Medea, G	1
Cricelli, C	1
Levin, PA	1
McLaughlin, J	1
Kowarski, AA	1
Balabolkin, MI	3
Nedosugova, LV	1
Gavriliuk, LM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Metformin as a Novel Treatment for Vitiligo by Targeting CD8+ T Cell Metabolism[NCT05607316]	Phase 2	30 participants (Anticipated)	Interventional	2023-05-01	Recruiting
The Effect of Multi-strain Probiotics on Gastrointestinal Symptoms in Patients With Type 2 Diabetes and Metformin Intolerance. A 32-week Prospective, Single Center, Randomized, Placebo Controlled, Cross-over Clinical Trial.[NCT04089280]		37 participants (Actual)	Interventional	2018-10-16	Completed
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513]		414 participants (Anticipated)	Interventional	2022-03-24	Not yet recruiting
"Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692]	Phase 3	60 participants (Anticipated)	Interventional	2021-12-10	Recruiting
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821]	Phase 3	168 participants (Actual)	Interventional	2018-07-12	Terminated (stopped due to Manufacturer discontinued the production of study drugs.)
A 52-week, Randomised, Multi-centre, Parallel Group Study to Investigate the Safety and Efficacy of BI 10773 (10 mg or 25 mg Administered Orally Once Daily) as add-on Therapy to an Oral Antidiabetic Drug (Sulfonylurea, Biguanide, Thiazolidinedione, Alpha [NCT01368081]	Phase 3	1,162 participants (Actual)	Interventional	2011-05-31	Completed
Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2018-07-07	Recruiting
Evaluation of Efficacy and Safety of HMR1964 Intensive Therapy in Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled With Oral Hypoglycemic Agents (OHA); OHA Therapy Controlled, Open, Randomized, Parallel Group, Comparative (Superiority), 16-[NCT00290927]	Phase 3	390 participants	Interventional	2003-12-31	Completed
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601]	Phase 3	170 participants	Interventional	2005-02-28	Completed
Open-Label Study Of Metformin In Combination With Simvastatin For Men With Prostate Carcinoma And A Rising Serum Prostate-Specific Antigen Level After Radical Prostatectomy And/Or Radiation Therapy[NCT01561482]	Phase 2	0 participants (Actual)	Interventional	2012-01-31	Withdrawn (stopped due to Study closed due to slow/low enrollment; no subjects were enrolled.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change from baseline in HbA1c after 52 weeks of treatment (NCT01368081)
Timeframe: Baseline and 52 weeks

Confirmed Hypoglycaemic Adverse Events

Intervention	percentage of HbA1c (Least Squares Mean)
Sulfonylurea: Empa 10mg	-0.93
Sulfonylurea: Empa 25mg	-0.96
Sulfonylurea: Metformin	-0.97
Biguanide: Empa 10mg	-0.81
Biguanide: Empa 25mg	-0.98
Thiazolidinedione: Empa 10mg	-0.90
Thiazolidinedione: Empa 25mg	-0.96
Alpha Glucosidase Inhibitor: Empa 10mg	-0.87
Alpha Glucosidase Inhibitor: Empa 25mg	-0.77
DPP-IV Inhibitor: Empa 10mg	-1.00
DPP-IV Inhibitor: Empa 25mg	-0.83
Glinide: Empa 10mg	-0.98
Glinide: Empa 25mg	-0.98

Number of patients with confirmed hypoglycaemic adverse events (NCT01368081)
Timeframe: After the first drug intake until 7 days after the last treatment administration, up to 383 days

Number of Patients With Drug Related Adverse Events

Intervention	participants (Number)
Sulfonylurea: Empa 10mg	6
Sulfonylurea: Empa 25mg	9
Sulfonylurea: Metformin	5
Biguanide: Empa 10mg	0
Biguanide: Empa 25mg	1
Thiazolidinedione: Empa 10mg	2
Thiazolidinedione: Empa 25mg	1
Alpha Glucosidase Inhibitor: Empa 10mg	0
Alpha Glucosidase Inhibitor: Empa 25mg	0
DPP-IV Inhibitor: Empa 10mg	0
DPP-IV Inhibitor: Empa 25mg	1
Glinide: Empa 10mg	0
Glinide: Empa 25mg	2

Number of Patients With Drug Related Adverse Events after the first drug intake until 7 days after the last treatment administration, up to 383 days (NCT01368081)
Timeframe: After the first drug intake until 7 days after the last treatment administration, up to 383 days

Article	Year
Perioperative Management of Oral Glucose-lowering Drugs in the Patient with Type 2 Diabetes. Anesthesiology, 2020, Volume: 133, Issue:2 Topics: Administration, Oral; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV	2020
Biguanides: Species with versatile therapeutic applications. European journal of medicinal chemistry, 2021, Jul-05, Volume: 219 Topics: Anti-Infective Agents; Antineoplastic Agents; Biguanides; Diabetes Mellitus, Type 2; Female; Humans;	2021
New insights into antidiabetic drugs: Possible applications in cancer treatment. Chemical biology & drug design, 2017, Volume: 90, Issue:6 Topics: AMP-Activated Protein Kinase Kinases; Biguanides; Cell Proliferation; Diabetes Mellitus, Type 2; Hum	2017
Metformin: clinical use in type 2 diabetes. Diabetologia, 2017, Volume: 60, Issue:9 Topics: Animals; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin	2017
The mechanisms of action of metformin. Diabetologia, 2017, Volume: 60, Issue:9 Topics: AMP-Activated Protein Kinases; Animals; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic	2017
The mechanisms of action of metformin. Diabetologia, 2017, Volume: 60, Issue:9 Topics: AMP-Activated Protein Kinases; Animals; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic	2017
The mechanisms of action of metformin. Diabetologia, 2017, Volume: 60, Issue:9 Topics: AMP-Activated Protein Kinases; Animals; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic	2017
The mechanisms of action of metformin. Diabetologia, 2017, Volume: 60, Issue:9 Topics: AMP-Activated Protein Kinases; Animals; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic	2017
Activation of AMPK by Medicinal Plants and Natural Products: Its Role in Type 2 Diabetes Mellitus. Mini reviews in medicinal chemistry, 2019, Volume: 19, Issue:11 Topics: AMP-Activated Protein Kinases; Biguanides; Biological Products; Diabetes Mellitus, Type 2; Glucose;	2019
Complications of diabetes therapy. Endocrinology and metabolism clinics of North America, 2013, Volume: 42, Issue:4 Topics: Biguanides; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Huma	2013
A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:11 Topics: Biguanides; Diabetes Mellitus, Type 2; Drug Administration Schedule; Humans; Hypoglycemic Agents; In	2014
Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here? Journal of internal medicine, 2015, Volume: 277, Issue:2 Topics: Administration, Oral; Biguanides; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Base	2015
The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:15 Topics: Biguanides; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors	2015
Repurposing metformin: an old drug with new tricks in its binding pockets. The Biochemical journal, 2015, Nov-01, Volume: 471, Issue:3 Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei	2015
Repurposing metformin: an old drug with new tricks in its binding pockets. The Biochemical journal, 2015, Nov-01, Volume: 471, Issue:3 Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei	2015
Repurposing metformin: an old drug with new tricks in its binding pockets. The Biochemical journal, 2015, Nov-01, Volume: 471, Issue:3 Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei	2015
Repurposing metformin: an old drug with new tricks in its binding pockets. The Biochemical journal, 2015, Nov-01, Volume: 471, Issue:3 Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei	2015
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nature reviews. Endocrinology, 2016, Volume: 12, Issue:10 Topics: Benzamides; Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy,	2016
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes? Current diabetes reports, 2017, Volume: 17, Issue:4 Topics: Biguanides; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents	2017
Type 2 diabetes: the many facets of care. Home healthcare nurse, 2008, Volume: 26, Issue:6 Topics: Adult; Amyloid; Biguanides; Community Health Nursing; Diabetes Mellitus, Type 2; Diabetic Foot; Dipe	2008
Drugs for type 2 diabetes. Treatment guidelines from the Medical Letter, 2008, Volume: 6, Issue:71 Topics: alpha-Galactosidase; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinati	2008
[Effectiveness of oral hypoglycemic drugs in the metabolic control of patients with gestational diabetes]. Revista medica de Chile, 2008, Volume: 136, Issue:7 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans;	2008
Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention. Canadian journal of physiology and pharmacology, 2009, Volume: 87, Issue:1 Topics: Animals; Biguanides; Catheterization; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Di	2009
[Diabetes mellitus of elderly patients: therapeutic recommendations]. La Tunisie medicale, 2008, Volume: 86, Issue:11 Topics: Aged; Aging; Biguanides; Blood Glucose; Cachexia; Diabetes Mellitus, Type 2; Diabetic Neuropathies;	2008
Oral anti-diabetic drugs for the prevention of Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:8 Topics: Administration, Oral; alpha-Glucosidases; Biguanides; Diabetes Mellitus, Type 2; Female; Humans; Hyp	2011
Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:10 Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Pe	2011
[Biguanides]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 1 Topics: Biguanides; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Metabolic Syndrome	2011
Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics, 2011, Volume: 12, Issue:8 Topics: Administration, Oral; Animals; Biguanides; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2	2011
Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature. Endocrine journal, 2012, Volume: 59, Issue:4 Topics: Aged, 80 and over; Biguanides; Blood Glucose; Depressive Disorder; Diabetes Mellitus, Type 2; Dipept	2012
Evolving therapeutic options for type 2 diabetes mellitus: an overview. Postgraduate medicine, 2012, Volume: 124, Issue:6 Topics: Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agen	2012
Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus. The American journal of cardiology, 2002, Sep-05, Volume: 90, Issue:5A Topics: Administration, Oral; Antihypertensive Agents; Biguanides; Diabetes Mellitus, Type 2; Glucosamine; H	2002
When diet fails: insulin and oral hypoglycemic agents as alternatives for the management of gestational diabetes mellitus. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2002, Volume: 11, Issue:4 Topics: Administration, Oral; Biguanides; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetes, Ges	2002
[Pharmacologic profile of oral antidiabetic agents]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hy	2002
[Structure and mechanisms of action of biguanides]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Animals; Biguanides; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Intestinal Abs	2002
[Metformin--its regimen and effects]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Acarbose; Biguanides; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therap	2002
[Adverse effect of biguanides]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Acidosis, Lactic; Biguanides; Diabetes Mellitus, Type 2; Gastrointestinal Diseases; Humans; Hypoglyc	2002
[Clinical usefulness of treatment with biguanide and insulin]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Biguanides; Buformin; Clinical Trials as Topic; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug	2002
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Acarbose; Animals; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug T	2002
Oral antihyperglycemic agents during pregnancy and lactation: a review. Paediatric drugs, 2002, Volume: 4, Issue:11 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans;	2002
[Combination therapy with biguanides]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 10 Topics: Acarbose; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, C	2002
Insulin sensitizers. Mayo Clinic proceedings, 2003, Volume: 78, Issue:4 Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin	2003
Treating type 2 diabetes: targeting the many causative factors. The Journal of family practice, 2004, Volume: 53, Issue:5 Topics: Algorithms; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic A	2004
Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint. Herz, 2004, Volume: 29, Issue:3 Topics: Administration, Oral; Benzamides; Biguanides; Diabetes Mellitus, Type 2; Drug Combinations; Glycosid	2004
Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005, Jan-18, Volume: 172, Issue:2 Topics: Acarbose; Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside	2005
Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs, 2005, Volume: 65, Issue:3 Topics: Biguanides; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents;	2005
A comparison of agents used to manage type 2 diabetes mellitus: need for reappraisal of traditional approaches. Treatments in endocrinology, 2004, Volume: 3, Issue:2 Topics: Animals; Benzamides; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Glyc	2004
[Selection of oral antidiabetic drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 2 Topics: Acarbose; Administration, Oral; Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Enzy	2005
[Characteristic of metformin for treatment of impaired glucose tolerance]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 2 Topics: Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Glucose; Glucose Intolerance; Humans; Hypog	2005
Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treatments in endocrinology, 2003, Volume: 2, Issue:1 Topics: Amyloid; Benzamides; Biguanides; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes	2003
[Glycemic control and diabetic complications]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 6 Topics: Biguanides; Biomarkers; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 1;	2005
[Knack of treatment with oral hypoglycemic drugs in the elderly]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:1 Topics: Aged; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glyburide; Humans; Hypoglyce	2006
AMP-activated protein kinase as a drug target. Annual review of pharmacology and toxicology, 2007, Volume: 47 Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Biguanides; Diabetes Mellitus, Type 2; Drug De	2007
Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. The American journal of cardiology, 2007, Feb-19, Volume: 99, Issue:4A Topics: Administration, Oral; Benzamides; Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gl	2007
Oral antidiabetic agents in type 2 diabetes. Current medical research and opinion, 2007, Volume: 23, Issue:4 Topics: Adenosine Deaminase Inhibitors; Administration, Oral; Benzamides; Biguanides; Diabetes Mellitus, Typ	2007
[Chronic kidney disease and antidiabetic treatment]. Revue medicale suisse, 2007, Mar-07, Volume: 3, Issue:101 Topics: Biguanides; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chron	2007
Are you up-to-date on diabetes medications? Nursing, 2007, Volume: 37, Issue:7 Topics: Amyloid; Benzamides; Biguanides; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2	2007
Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus. Current drug discovery technologies, 2007, Volume: 4, Issue:1 Topics: Administration, Inhalation; Benzamides; Benzoates; Biguanides; Blood Glucose; Diabetes Mellitus, Typ	2007
Metabolic syndrome: from global epidemiology to individualized medicine. Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:5 Topics: Anti-Obesity Agents; Bariatric Surgery; Biguanides; Body Mass Index; Caloric Restriction; Cardiovasc	2007
Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2007, Volume: 127, Issue:10 Topics: Administration, Oral; Biguanides; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination;	2007
Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug safety, 2007, Volume: 30, Issue:12 Topics: Amyloid; Benzamides; Biguanides; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inh	2007
The utility of oral diabetes medications in type 2 diabetes of the young. Current diabetes reviews, 2005, Volume: 1, Issue:1 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosidases; Humans	2005
Type 2 diabetes and oral antihyperglycemic drugs. Current medicinal chemistry, 2008, Volume: 15, Issue:1 Topics: Administration, Oral; Animals; Benzamides; Biguanides; Clinical Trials as Topic; Diabetes Mellitus,	2008
Management of diabetes. The Journal of the Association of Physicians of India, 1983, Volume: 31, Issue:4 Topics: Biguanides; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet, Diabetic; Exercise Therapy;	1983
[Physiologic and physiopathologic implications of insulin-receptor interaction (II). Pathologic situations in which changes in insulin-receptor interaction are detected]. Medicina clinica, 1984, Apr-14, Volume: 82, Issue:14 Topics: Acanthosis Nigricans; Animals; Biguanides; Child; Diabetes Complications; Diabetes Mellitus, Type 1;	1984
[Insulin receptor and postreceptor disorders: significance for the development and therapy of carbohydrate metabolic disorders]. Acta medica Austriaca, 1984, Volume: 11, Issue:3-4 Topics: Autoantibodies; Biguanides; Body Weight; Carbohydrate Metabolism, Inborn Errors; Diabetes Mellitus;	1984
Comparative tolerability profiles of oral antidiabetic agents. Drug safety, 1994, Volume: 11, Issue:4 Topics: Acarbose; Administration, Oral; Biguanides; Biological Availability; Diabetes Mellitus, Type 2; Drug	1994
Some thoughts on the treatment of non-insulin-dependent diabetes mellitus. Acta clinica Belgica, 1993, Volume: 48, Issue:4 Topics: Algorithms; Biguanides; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise; Humans; Insu	1993
Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes. Acta clinica Belgica, 1993, Volume: 48, Issue:4 Topics: Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Hu	1993
[Drug therapy of type-II diabetes: tablets, insulin or a combination of these]. Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1994, Jan-18, Volume: 83, Issue:3 Topics: Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insul	1994
Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). Drugs, 1995, Volume: 50, Issue:2 Topics: Acarbose; Aldehyde Reductase; Biguanides; Diabetes Mellitus, Type 2; Glucose; Guanidines; Humans; Hy	1995
Metformin: a new treatment option for non-insulin-dependent diabetes mellitus. The Journal of family practice, 1996, Volume: 42, Issue:6 Topics: Biguanides; Diabetes Mellitus, Type 2; Drug Interactions; Glyburide; Humans; Hypoglycemic Agents; In	1996
Oral antidiabetic drugs: an overview. Diabetic medicine : a journal of the British Diabetic Association, 1996, Volume: 13, Issue:9 Suppl 6 Topics: Biguanides; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glucose Int	1996
[Drug therapy in subjects with impaired glucose tolerance]. Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:10 Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase	1996
Cardiovascular effects of oral hypoglycaemic drugs. Clinical and experimental pharmacology & physiology, 1996, Volume: 23, Issue:3 Topics: Biguanides; Diabetes Mellitus, Type 2; Glyburide; Heart; Hemodynamics; Humans; Hypoglycemic Agents;	1996
[Long-term biguanide treatment in the natural evolution of NIDDM]. Journees annuelles de diabetologie de l'Hotel-Dieu, 1996 Topics: Biguanides; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Time Factors	1996
Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus. Drugs & aging, 1997, Volume: 10, Issue:5 Topics: Administration, Oral; Aged; Aging; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination;	1997
[Value of biguanide in therapy of diabetes mellitus]. Medizinische Klinik (Munich, Germany : 1983), 1997, Aug-15, Volume: 92, Issue:8 Topics: Biguanides; Blood Glucose; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents	1997
[Possible primary prevention of NIDDM (type 2 diabetes) by pharmacological interventions]. Nihon rinsho. Japanese journal of clinical medicine, 1997, Volume: 55 Suppl Topics: Aged; Biguanides; Diabetes Mellitus, Type 2; Female; Glycoside Hydrolase Inhibitors; Humans; Hypogly	1997
Treatment of type 2 diabetes mellitus. The Medical clinics of North America, 1998, Volume: 82, Issue:4 Topics: Biguanides; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Diet, Diabetic; Exercise Therapy; Gl	1998
[Pitfalls in treatment with oral antidiabetic agents]. Vnitrni lekarstvi, 1998, Volume: 44, Issue:1 Topics: Acarbose; Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents;	1998
The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocrine reviews, 1998, Volume: 19, Issue:5 Topics: Acarbose; Adult; Aged; Aged, 80 and over; Arteriosclerosis; Biguanides; Blood Glucose; Cardiovascula	1998
Oral agent therapy in the treatment of type 2 diabetes. Diabetes care, 1999, Volume: 22 Suppl 3 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhib	1999
[Therapeutic utility of biguanides in the treatment of NIDDM]. Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:3 Topics: Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin	1999
[Etiology and therapy of insulin resistance]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1999, Sep-10, Volume: 88, Issue:9 Topics: Animals; Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertens	1999
Improving management of type 2 diabetes mellitus: 2. Biguanides. Hospital practice (1995), 1999, Oct-15, Volume: 34, Issue:11 Topics: Biguanides; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Humans; Hypogly	1999
[Approach to diabetic therapy. 2. Selection and the use of oral antidiabetics. 3) Biguanides and alpha-glucosidase inhibitors]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2000, Aug-10, Volume: 89, Issue:8 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans;	2000
Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs, 2000, Volume: 60, Issue:5 Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Risk Fac	2000
Effects of current therapeutic interventions on insulin resistance. Diabetes, obesity & metabolism, 1999, Volume: 1 Suppl 1 Topics: Biguanides; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet; Enzyme Inhibitors; Exercise; Glycosi	1999
[Update on new oral treatment for diabetes]. Harefuah, 2001, Volume: 140, Issue:1 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhib	2001
Lactic acidosis update for critical care clinicians. Journal of the American Society of Nephrology : JASN, 2001, Volume: 12 Suppl 17 Topics: Acidosis, Lactic; Biguanides; Critical Care; Diabetes Mellitus, Type 2; Humans	2001
Oral agents in the management of type 2 diabetes mellitus. American family physician, 2001, May-01, Volume: 63, Issue:9 Topics: Benzamides; Biguanides; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglyce	2001
[Current and future aspects of oral antidiabetic agents in type 2 diabetes]. Vnitrni lekarstvi, 2001, Volume: 47, Issue:5 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans;	2001
Type 2 diabetes. How new insights, new drugs are changing clinical practice. Geriatrics, 2001, Volume: 56, Issue:6 Topics: Acarbose; Aged; Biguanides; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug	2001
Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Annals of emergency medicine, 2001, Volume: 38, Issue:1 Topics: Administration, Oral; Benzoates; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Drug Interact	2001
[Clinical difference between thiazolidinediones and biguanides]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:11 Topics: Biguanides; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combin	2001
Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA, 2002, Jan-16, Volume: 287, Issue:3 Topics: Administration, Oral; Biguanides; Blood Glucose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Di	2002
Treatment of type 2 diabetes mellitus: pharmacologic intervention. The Journal of cardiovascular nursing, 2002, Volume: 16, Issue:2 Topics: Benzamides; Biguanides; Diabetes Mellitus, Type 2; Glucosidases; Humans; Hypoglycemic Agents; Insuli	2002
Type 2 diabetes therapy. A pathophysiologically based approach. Postgraduate medicine, 2002, Volume: 111, Issue:3 Topics: alpha-Glucosidases; Benzamides; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents;	2002
[Therapeutic renaissance. Biguanides in type-2 diabetes: metformin]. Pharmazie in unserer Zeit, 2002, Volume: 31, Issue:3 Topics: Animals; Biguanides; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agent	2002
Biguanide-associated lactic acidosis. Case report and review of the literature. Archives of internal medicine, 1992, Volume: 152, Issue:11 Topics: Acidosis, Lactic; Biguanides; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Emigration and Immi	1992
[Oral and dietary treatments of type 2 diabetes]. La Revue du praticien, 1992, May-01, Volume: 42, Issue:9 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents	1992
Biguanides and NIDDM. Diabetes care, 1992, Volume: 15, Issue:6 Topics: Adipose Tissue; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic	1992
Pharmacokinetic optimisation of oral hypoglycaemic therapy. Clinical pharmacokinetics, 1991, Volume: 21, Issue:4 Topics: Administration, Oral; Biguanides; Biological Availability; Diabetes Mellitus, Type 2; Drug Interacti	1991
Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes care, 1990, Volume: 13 Suppl 3 Topics: Adult; Aged; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Lipid Metabol	1990
Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clinical pharmacokinetics, 1989, Volume: 16, Issue:2 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylur	1989
[Oral therapy of type II diabetes]. Medizinische Klinik (Munich, Germany : 1983), 1989, Apr-15, Volume: 84, Issue:4 Topics: Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds	1989
The use of oral hypoglycaemic agents in the treatment of diabetes mellitus. The Medical journal of Australia, 1987, May-04, Volume: 146, Issue:9 Topics: Administration, Oral; Biguanides; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypog	1987

Article	Year
Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:9 Topics: Asian People; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Femal	2013
Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:7 Topics: Adult; Aged; Benzhydryl Compounds; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-	2015
Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:10 Topics: Aged; Biguanides; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedul	2015
Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. Endocrine journal, 2016, Volume: 63, Issue:3 Topics: Aged; Biguanides; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blin	2016
Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:9 Topics: Benzofurans; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor	2016
The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:12 Topics: Asian People; Biguanides; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combi	2016
The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes. Lipids in health and disease, 2016, Aug-27, Volume: 15, Issue:1 Topics: Adult; Apolipoprotein A-I; Biguanides; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, D	2016
A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial. Diabetes, obesity & metabolism, 2016, Volume: 18 Suppl 2 Topics: Aged; Alanine Transaminase; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptida	2016
Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:9 Topics: Aged; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyca	2009
Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control. Atherosclerosis, 2003, Volume: 166, Issue:1 Topics: Adult; Apolipoproteins B; Biguanides; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Dietary Fats; Do	2003
Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis. Clinical cardiology, 2007, Volume: 30, Issue:6 Topics: Aged; Biguanides; Blood Coagulation Factors; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dru	2007
Comparative tolerability profiles of oral antidiabetic agents. Drug safety, 1994, Volume: 11, Issue:4 Topics: Acarbose; Administration, Oral; Biguanides; Biological Availability; Diabetes Mellitus, Type 2; Drug	1994
[Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions]. Przeglad lekarski, 1999, Volume: 56, Issue:5 Topics: Acarbose; Adult; Aged; Aged, 80 and over; Biguanides; Body Mass Index; Carbohydrate Metabolism; Chol	1999
Effect of omega-3 fatty acids on lipid peroxidation and antioxidant enzyme status in type 2 diabetic patients. Diabetes & metabolism, 2002, Volume: 28, Issue:1 Topics: Administration, Oral; Antioxidants; Biguanides; Blood Glucose; Catalase; Cholesterol; Diabetes Melli	2002
[Is it permissible to treat young diabetics with oral antidiabetics?]. Orvosi hetilap, 1991, Jun-09, Volume: 132, Issue:23 Topics: Administration, Oral; Adolescent; Adult; Age Factors; Biguanides; Child; Child, Preschool; Contraind	1991
The use of oral hypoglycaemic agents in the treatment of diabetes mellitus. The Medical journal of Australia, 1987, May-04, Volume: 146, Issue:9 Topics: Administration, Oral; Biguanides; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypog	1987

Article	Year
Current status of diabetes treatment in Miyazaki Prefecture, Japan: Results of a questionnaire survey conducted in 2016 and 2020. Journal of diabetes investigation, 2022, Volume: 13, Issue:6 Topics: Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Japan; Sodium-Glucose Transporte	2022
Cardiac Dysfunction Due to Thiamine Deficiency after Hemodialysis for Biguanide-related Lactic Acidosis. Internal medicine (Tokyo, Japan), 2022, Oct-01, Volume: 61, Issue:19 Topics: Acidosis, Lactic; Beriberi; Biguanides; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglyce	2022
Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes. Pharmacoepidemiology and drug safety, 2022, Volume: 31, Issue:8 Topics: Biguanides; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glu	2022
Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes Mellitus in Japan from 2012-2020: a Time-Series Analysis. Biological & pharmaceutical bulletin, 2023, Volume: 46, Issue:4 Topics: Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and	2023
[Adherence to Oral Antihyperglycemic Agents (Dipeptidyl Peptidase-4 Inhibitors and Biguanides) and Its Associated Factors in Patients with Type 2 Diabetes]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2019, Volume: 139, Issue:12 Topics: Administration, Oral; Adult; Aged; Anxiety; Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptid	2019
Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands. BMJ open diabetes research & care, 2020, Volume: 8, Issue:1 Topics: Aged; Biguanides; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; G	2020
A Novel CGM Metric-Gradient and Combining Mean Sensor Glucose Enable to Improve the Prediction of Nocturnal Hypoglycemic Events in Patients with Diabetes. Journal of diabetes research, 2020, Volume: 2020 Topics: Aged; Biguanides; Blood Glucose; Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Mellitus,	2020
Structure and State of Water in Branched Molecules (Basel, Switzerland), 2020, Dec-18, Volume: 25, Issue:24 Topics: Biguanides; Diabetes Mellitus, Type 2; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interactio	2020
Alzheimer's Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort. Journal of Alzheimer's disease : JAD, 2021, Volume: 83, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Autopsy; Biguanides; Diabetes Mel	2021
Therapeutic inertia and intensified treatment in diabetes mellitus prescription patterns: A nationwide population-based study in Taiwan. The Journal of international medical research, 2016, Volume: 44, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycat	2016
Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015. PloS one, 2017, Volume: 12, Issue:6 Topics: Biguanides; Diabetes Mellitus, Type 2; Health Expenditures; Humans; Hypoglycemic Agents; Incretins;	2017
New Biguanides as Anti-Diabetic Agents Part I: Synthesis and Evaluation of 1-Substituted Biguanide Derivatives as Anti-Diabetic Agents of Type II Diabetes Insulin Resistant. Drug research, 2017, Volume: 67, Issue:10 Topics: Animals; Biguanides; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hypoglycemic Agents	2017
Metformin: historical overview. Diabetologia, 2017, Volume: 60, Issue:9 Topics: Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin	2017
New Biguanides as Anti-Diabetic Agents, Part II: Synthesis and Anti-Diabetic Properties Evaluation of 1-Arylamidebiguanide Derivatives as Agents of Insulin Resistant Type II Diabetes. Archiv der Pharmazie, 2017, Volume: 350, Issue:11 Topics: Administration, Oral; Animals; Biguanides; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type	2017
The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: An 8-year population-based study. Medicine, 2017, Volume: 96, Issue:43 Topics: Administration, Oral; Age Factors; Aged; Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase	2017
Mapping of biguanide transporters in human fat cells and their impact on lipolysis. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:10 Topics: Adipocytes; Adult; Aged; Animals; Biguanides; Biological Transport; Cells, Cultured; Diabetes Mellit	2018
[CHANGES OF LIFETIME MORPHOLOGICAL PARAMETERS OF THE RETINA ON THE BACKGROUND OF CORRECTION OF LIPID METABOLISM IN PATIENTSWITH TYPE 2 DIABETES MELLITUS]. Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994), 2017, Volume: 63, Issue:1 Topics: Aged; Biguanides; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate;	2017
Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution? The Journal of clinical endocrinology and metabolism, 2019, 01-01, Volume: 104, Issue:1 Topics: Adult; Aged; Apoptosis; Biguanides; Carcinoid Tumor; Cell Line, Tumor; Cell Movement; Cell Prolifera	2019
Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity. Journal of diabetes research, 2019, Volume: 2019 Topics: Adult; Aged; Atherosclerosis; Biguanides; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes M	2019
A new perspective on the biguanide, metformin therapy in type 2 diabetes and lactic acidosis. Journal of diabetes investigation, 2019, Volume: 10, Issue:4 Topics: Acidosis, Lactic; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pro	2019
Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study. Pharmacoepidemiology and drug safety, 2019, Volume: 28, Issue:9 Topics: Administrative Claims, Healthcare; Adolescent; Adult; Aged; Aged, 80 and over; Biguanides; Cardiovas	2019
[Morphological justification of the effectiveness of ultrasonic cavitation with 0.2]. Khirurgiia, 2019, Issue:7 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Local; Biguanides; D	2019
Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell, 2013, Mar-28, Volume: 153, Issue:1 Topics: Adenylate Kinase; Aging; Animals; Biguanides; Caenorhabditis elegans; Caenorhabditis elegans Protein	2013
Patenting carboxyformin in the United States: how does it work and what does it mean? Journal of diabetes science and technology, 2013, Mar-01, Volume: 7, Issue:2 Topics: Biguanides; Biomedical Research; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agen	2013
Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:3 Topics: Benzamides; Biguanides; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; M	2014
Use of biguanides and the risk of colorectal cancer: a register-based cohort study. Current drug safety, 2013, Volume: 8, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biguanides; Cohort Studies; Colorectal Neoplasms; Comorb	2013
Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes. Advances in medical sciences, 2013, Volume: 58, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Atherosclerosis; Biguanides; Cardiovascular Diseases; Coronary Ar	2013
[Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2014, Volume: 134, Issue:2 Topics: Acarbose; Administration, Oral; Adverse Drug Reaction Reporting Systems; Benzamides; Biguanides; Dat	2014
Estimation of visceral fat and fatty liver disease using ultrasound in patients with diabetes. Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:6 Topics: Aged; Biguanides; Body Composition; Body Mass Index; Diabetes Mellitus, Type 2; Diet, Western; Femal	2014
Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. The Biochemical journal, 2014, Sep-15, Volume: 462, Issue:3 Topics: Animals; Antimalarials; Antineoplastic Agents; Biguanides; Cattle; Diabetes Mellitus, Type 2; Electr	2014
Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide. Minerva endocrinologica, 2014, Volume: 39, Issue:4 Topics: Adult; Aged; Alanine Transaminase; Anthropometry; Biguanides; Body Weight; Comorbidity; Diabetes Mel	2014
[Biguanide]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:3 Topics: Biguanides; Diabetes Mellitus, Type 2; Humans	2015
Racial ethnic differences in type 2 diabetes treatment patterns and glycaemic control in the Boston Area Community Health Survey. BMJ open, 2015, May-12, Volume: 5, Issue:5 Topics: Adult; Aged; Biguanides; Black or African American; Blood Glucose; Boston; Diabetes Mellitus, Type 2	2015
Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database. BMC endocrine disorders, 2015, Sep-17, Volume: 15 Topics: Adult; Aged; Angina Pectoris; Biguanides; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Inf	2015
Case 14: Octenilin Wound Gel versus betadine/PHMB gel. Journal of wound care, 2016, Volume: 25, Issue:3 Suppl Topics: Adult; Anti-Infective Agents, Local; Biguanides; Diabetes Mellitus, Type 2; Diabetic Foot; Disinfect	2016
The Dramatic Recovery of a Patient with Biguanide-associated Severe Lactic Acidosis Following Thiamine Supplementation. Internal medicine (Tokyo, Japan), 2017, Volume: 56, Issue:4 Topics: Acidosis, Lactic; Aged; Biguanides; Diabetes Mellitus, Type 2; Dietary Supplements; Female; Humans;	2017
Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42). Medicine, 2017, Volume: 96, Issue:7 Topics: Age Factors; Aged; Biguanides; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl	2017
Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer. Prescrire international, 2009, Volume: 18, Issue:101 Topics: Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combi	2009
Diabetes under control: Understanding oral antidiabetic agents. The American journal of nursing, 2010, Volume: 110, Issue:2 Topics: Administration, Oral; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Dipeptidyl-Pe	2010
[Difference between biguanide and thiazolidinedione, and the significance of combination therapy of biguanide and thiazolidinedione]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:5 Topics: Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Insulin Resistance; Thiazo	2010
[Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69, Issue:8 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dru	2011
[Combination therapy of oral hypoglycemic agents which enhance the efficacy of insulin therapy]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 3 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Huma	2012
Central anti-diabetic action of biguanide and thizolidinediones in D-glucose fed and streptozotocin-treated mouse models. Neuroscience letters, 2012, Oct-18, Volume: 528, Issue:1 Topics: Animals; Biguanides; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type	2012
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature, 2013, Feb-14, Volume: 494, Issue:7436 Topics: Adenylyl Cyclases; AMP-Activated Protein Kinases; Animals; Biguanides; Cells, Cultured; Cyclic AMP;	2013
Should we screen diabetic patients using biguanides for megaloblastic anaemia? Australian family physician, 2003, Volume: 32, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anemia, Megaloblastic; Biguanides; Diabetes Mellitus, Type 2; Female	2003
The value of basal C peptide and its relationship with pancreatic autoantibodies in young adults with type 2 diabetes mellitus. Romanian journal of internal medicine = Revue roumaine de medecine interne, 2004, Volume: 42, Issue:2 Topics: Adult; Autoantibodies; Biguanides; Biomarkers; Body Mass Index; Body Weight; C-Peptide; Diabetes Mel	2004
[Glycemic control in type 2 diabetes patients with three drug treatment]. Medicina clinica, 2005, May-21, Volume: 124, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy,	2005
[Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France]. Revue d'epidemiologie et de sante publique, 2005, Volume: 53 Spec No 1 Topics: Adolescent; Adult; Aged; Aspirin; Biguanides; Cerebrovascular Disorders; Coronary Disease; Cost-Bene	2005
[Disseminated herpes zoster in diabetes mellitus]. Deutsche medizinische Wochenschrift (1946), 2006, Feb-24, Volume: 131, Issue:8 Topics: Acyclovir; Administration, Topical; Aged; Antiviral Agents; Biguanides; Blood Glucose; Diabetes Mell	2006
Biguanides enhance glucose utilization and insulin action in peripheral tissues: an old finding from the sixties of the last century. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2006, Volume: 38, Issue:10 Topics: Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Humans; Hypoglycemic Agents; I	2006
Metformin: preventable lactic acidosis. Prescrire international, 2007, Volume: 16, Issue:87 Topics: Acidosis, Lactic; Biguanides; Diabetes Mellitus, Type 2; Female; France; Humans; Male; Metformin	2007
Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. International journal of cardiology, 2008, May-23, Volume: 126, Issue:2 Topics: Aged; Biguanides; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Foll	2008
New treatments for diabetes. The New England journal of medicine, 2007, May-24, Volume: 356, Issue:21 Topics: Adenosine Deaminase Inhibitors; Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipep	2007
Clinical predictors of glycosylated hemoglobin response to thiazolidinedione therapy. Diabetes technology & therapeutics, 2007, Volume: 9, Issue:6 Topics: Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Human	2007
Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: a 4-year retrospective study from national primary care data. Pharmacological research, 2008, Volume: 57, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Aged; Biguanides; Databases, Factual; Diabetes Mellitus, Ty	2008
Diabetes mellitus: customizing management. Hospital practice (Office ed.), 1984, Volume: 19, Issue:10 Topics: Adult; Aging; Biguanides; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Ty	1984
[Effect of peroral blood glucose reducing therapy on insulin receptor interactions in patients with type II diabetes mellitus]. Terapevticheskii arkhiv, 1983, Volume: 55, Issue:9 Topics: Adult; Aged; Biguanides; Diabetes Mellitus, Type 2; Humans; Insulin; Middle Aged; Monocytes; Radioli	1983
Plasma HDL in non-insulin-dependent diabetes and the effect of various types of treatment. Atherosclerosis, 1983, Volume: 49, Issue:3 Topics: Adult; Aged; Biguanides; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Humans; H	1983
Oral hypoglycemic agents in type II diabetes mellitus. American family physician, 1995, Nov-15, Volume: 52, Issue:7 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Half-Life; Humans; Hypoglycemic Agents;	1995
New oral agents for type II diabetes. Taking a more aggressive approach to therapy. Postgraduate medicine, 1995, Volume: 98, Issue:6 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glycoside	1995
[How I treat... a non-obese patient with Type 2 diabetes]. Revue medicale de Liege, 1994, Mar-01, Volume: 49, Issue:3 Topics: Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin	1994
DIACATOR: simulation of metabolic abnormalities of type II diabetes mellitus by use of a personal computer. Computer methods and programs in biomedicine, 1994, Volume: 41, Issue:3-4 Topics: Acarbose; Biguanides; Computer Simulation; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Tes	1994
[The treatment characteristics of non-insulin-dependent diabetes mellitus]. Terapevticheskii arkhiv, 1996, Volume: 68, Issue:10 Topics: Biguanides; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Humans; Hypoglycem	1996
[The combined treatment of patients with type-2 diabetes mellitus]. Voenno-meditsinskii zhurnal, 1996, Volume: 317, Issue:11 Topics: Acarbose; Biguanides; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Female;	1996
Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients. Diabetes research and clinical practice, 1997, Volume: 36, Issue:3 Topics: Administration, Oral; Aged; Apolipoproteins; Biguanides; Blood Glucose; Blood Pressure; Body Constit	1997
[Biguanide and elective anesthesia]. Der Anaesthesist, 1998, Volume: 47, Issue:6 Topics: Biguanides; Diabetes Mellitus, Type 2; Elective Surgical Procedures; Humans; Hypoglycemic Agents	1998
Targeted glycemic control in type 2 diabetes. The Journal of the Florida Medical Association, 1998, Volume: 85, Issue:2 Topics: Aged; Algorithms; Anti-Obesity Agents; Biguanides; Blood Glucose; Blood Glucose Self-Monitoring; Chr	1998
[What is new about diabetes mellitus, type 2?]. Krankenpflege Journal, 1999, Volume: 37, Issue:6 Topics: Biguanides; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hyperinsulinism; Kidney Failure, Chron	1999
[The COMBO project. Criteria and guidelines for the combined treatment of type 2 diabetes. Consensus document (I)]. Atencion primaria, 2001, Feb-28, Volume: 27, Issue:3 Topics: Algorithms; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrolase In	2001
Oral antihyperglycemic therapy for type 2 diabetes: clinical applications. JAMA, 2002, Jan-16, Volume: 287, Issue:3 Topics: Aged; Biguanides; Comorbidity; Decision Making; Diabetes Mellitus, Type 2; Drug Therapy, Combination	2002
Type 2 diabetes in obese white children. Archives of disease in childhood, 2002, Volume: 86, Issue:3 Topics: Adolescent; Biguanides; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female	2002
Effect of bed time intermediate acting insulin in NIDDM subjects refractory to a combination of sulphonylureas and biguanides. The Journal of the Association of Physicians of India, 1992, Volume: 40, Issue:10 Topics: Biguanides; Blood Glucose; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Combinations; Female; Gli	1992
Biguanide related lactic acidosis: incidence and risk factors. Archives of medical research, 1992,Spring, Volume: 23, Issue:1 Topics: Acidosis, Lactic; Adolescent; Adult; Aged; Aged, 80 and over; Biguanides; Contraindications; Diabete	1992
[Biguanides in diabetes therapy. New aspects with special regard to the metabolic syndrome. Satellite symposium of the 2nd German Physicians' Conference. Dresden, 15 June 1991]. Der Internist, 1991, Volume: 32, Issue:8 Suppl Topics: Biguanides; Diabetes Mellitus, Type 2; Humans	1991
[Oral antidiabetic agents: what are the choices?]. Revue medicale de la Suisse romande, 1991, Volume: 111, Issue:8 Topics: Adult; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Middle Aged; Sulfonylurea	1991
[Secondary sulfonylurea failure]. Deutsche medizinische Wochenschrift (1946), 1991, May-24, Volume: 116, Issue:21 Topics: Biguanides; Diabetes Mellitus, Type 2; Humans; Sulfonylurea Compounds	1991
[Effect of biguanides on the indicators of thrombelastography and the level of lactic acid in diabetes mellitus]. Sovetskaia meditsina, 1990, Issue:12 Topics: Adolescent; Adult; Aged; Biguanides; Blood Coagulation; Diabetes Mellitus, Type 1; Diabetes Mellitus	1990
Management of non-insulin-dependent diabetes. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1990, Dec-01, Volume: 78 Suppl Topics: Aged; Biguanides; Diabetes Mellitus, Type 2; Humans; Sulfonylurea Compounds	1990
[Spectrum of erythrocyte membrane lipids in various types of hypoglycemic therapy]. Sovetskaia meditsina, 1990, Issue:6 Topics: Biguanides; Cholesterol; Chromatography; Diabetes Mellitus, Type 2; Erythrocyte Membrane; Female; Gl	1990
[Sulfonylurea compounds or biguanides in the treatment of type 2 diabetes?]. Deutsche medizinische Wochenschrift (1946), 1989, Jul-07, Volume: 114, Issue:27 Topics: Aged; Animals; Biguanides; Cricetinae; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glyburi	1989
[Biguanide derivatives in diabetes mellitus]. Sovetskaia meditsina, 1989, Issue:4 Topics: Adolescent; Adult; Biguanides; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, C	1989
Delaying carbohydrate absorption in noninsulin-dependent diabetes mellitus: useful therapy? Klinische Wochenschrift, 1987, May-04, Volume: 65, Issue:9 Topics: Acarbose; Biguanides; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus; Diabetes Mellitus	1987
[New trends in the treatment of diabetes mellitus]. Klinicheskaia meditsina, 1986, Volume: 64, Issue:3 Topics: Animals; Biguanides; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary F	1986
Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril. The New England journal of medicine, 1988, Dec-15, Volume: 319, Issue:24 Topics: Biguanides; Captopril; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female;	1988
[Treatment of diabetes mellitus]. Fel'dsher i akusherka, 1987, Volume: 52, Issue:3 Topics: Biguanides; Combined Modality Therapy; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet, D	1987
[Oral antidiabetic agents including glucosidase inhibitors]. Der Internist, 1987, Volume: 28, Issue:4 Topics: Administration, Oral; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; G	1987
[Oral antidiabetic agents, yes but...]. Revue medicale de Bruxelles, 1988, Volume: 9, Issue:3 Topics: Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds	1988
[The biguanides]. Soins; la revue de reference infirmiere, 1987, Issue:507 Topics: Biguanides; Diabetes Mellitus, Type 2; Humans	1987
[Incidence of severe secondary effects during treatment with sulfonylureas and biguanides]. Journees annuelles de diabetologie de l'Hotel-Dieu, 1986 Topics: Adult; Aged; Biguanides; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Inappropriate ADH	1986
[Guidelines of the Swiss Diabetic Association concerning oral antidiabetic agents]. Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1986, May-20, Volume: 75, Issue:21 Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Societies,	1986
[Circadian profiles of lactic and pyruvic acid in diabetic patients treated with biguanides and sulfonylureas]. La Clinica terapeutica, 1986, Aug-31, Volume: 118, Issue:4 Topics: Aged; Biguanides; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Diet, Diabetic; Humans	1986
Incidence of severe sideeffects during therapy with sulfonylureas and biguanides. Hormone and metabolic research. Supplement series, 1985, Volume: 15 Topics: Acidosis; Biguanides; Chlorpropamide; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Hypog	1985
[Possibilities and limits of oral diabetes therapy]. Wiener medizinische Wochenschrift (1946), 1985, Apr-15, Volume: 135, Issue:6-7 Topics: Administration, Oral; Biguanides; Combined Modality Therapy; Diabetes Mellitus; Diabetes Mellitus, T	1985
[Alteration of blood lactic acid levels in biguanide therapy in diabetics]. Sichuan yi xue yuan xue bao = Acta Academiae Medicinae Sichuan, 1985, Volume: 16, Issue:2 Topics: Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Humans; Lactates; Lacti	1985

biguanides and Diabetes Mellitus, Adult-Onset